

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM362391

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Assignment of Intellectual Property Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
GENERAL ELECTRIC CAPITAL CORPORATION, as Retiring Agent		11/13/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	HEALTHCARE FINANCIAL SOLUTIONS, LLC, as Successor Agent		
Street Address:	2 Bethesda Metro Center Suite 600		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20814-5318		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 32			
Property Type	Number	Word Mark	
Registration Number:	4146108	ARBOR PHARMACEUTICALS, INC.	
Registration Number:	1077242	E.E.S.	
Registration Number:	1058892	E.E.S. 400	
Registration Number:	1144690	EES	
Registration Number:	1082192	ERYDERM	
Registration Number:	1251456	ERYPED	
Registration Number:	1211217	ERY-TAB	
Registration Number:	0590748	ERYTHROCIN	
Registration Number:	3544687	NEOTIC	
Registration Number:	1437037	PCE	
Registration Number:	3881019	PEDIADERM	
Registration Number:	3632499	XYLAREX	
Registration Number:	3350351	ZINOTIC	
Registration Number:	1896747	BIDIL	
Registration Number:	3604276	HEART HEALTH HERITAGE	
Registration Number:	3092262	MAKING TODAY'S BEST MEDICINES BETTER	
Registration Number:	3265101	MORE LIFE TO LIVE	
Registration Number:	3177849	N	

CH \$815.00 4146108

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	3904570	N
Registration Number:	2897976	NITROMED
Registration Number:	2621465	NITROMED
Registration Number:	3588941	NITROMED
Registration Number:	3335303	NITROMED CARES
Serial Number:	85748821	ARBOR PHARMACEUTICALS
Serial Number:	85373407	EQUADD
Serial Number:	85560877	EXERSCORE
Serial Number:	85560878	EXERSCRIPT
Serial Number:	85404726	NYMALIZE
Serial Number:	85833131	BALADD
Serial Number:	85550865	ZENZEDI
Serial Number:	85154611	BIDIL XR
Serial Number:	85749031	WILSHIRE PHARMACEUTICALS

CORRESPONDENCE DATA

Fax Number: 4045725135

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 404-572-3493

Email: kosborne@kslaw.com

Correspondent Name: Karen Osborne, Senior Paralegal

Address Line 1: 1180 Peachtree Street, N.E.

Address Line 2: King & Spalding LLP

Address Line 4: Atlanta, GEORGIA 30309

ATTORNEY DOCKET NUMBER: 09642.015087 ARBOR

NAME OF SUBMITTER: Karen Osborne

SIGNATURE: //Karen Osborne//

DATE SIGNED: 11/15/2015

Total Attachments: 8

source=Arbor Executed Assignment of Intellectual Property Security Agreement#page1.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page2.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page3.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page4.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page5.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page6.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page7.tif
source=Arbor Executed Assignment of Intellectual Property Security Agreement#page8.tif

**ASSIGNMENT OF INTELLECTUAL PROPERTY
SECURITY AGREEMENT**

This **ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this “**Assignment**”), dated as of November 13, 2015, is by **GENERAL ELECTRIC CAPITAL CORPORATION**, (as the current and resigning administrative agent, the “**Retiring Agent**”) and **HEALTHCARE FINANCIAL SOLUTIONS, LLC**¹, (as the successor administrative agent together with its successors and assigns, the “**Successor Agent**”).

RECITALS:

WHEREAS, ARBOR PHARMACEUTICALS, LLC (parent and successor by merger with its former subsidiary, Nitromed, Inc.) and WILSHIRE PHARMACEUTICALS, INC. (each individually and collectively, as “**Grantor**”), and Retiring Agent are parties to one or more intellectual property security agreements identified in Exhibit A attached hereto (as the same have been and may hereafter be amended, restated, supplemented or otherwise modified from time to time, collectively, the “**Agreements**”) pursuant to which Grantor granted a security interest in and to and lien upon the intellectual property identified in Exhibit B (the “**Subject IP**”); and

WHEREAS, pursuant to that certain Omnibus Agency Transfer Agreement by and between Retiring Agent and Successor Agent, Retiring Agent has assigned to Successor Agent all of its rights, remedies, duties and other obligations under, among other documents, the Agreements and the Subject IP, in each instance, in its capacity as administrative agent and collateral agent, as the case may be.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Retiring Agent hereby assigns and transfers to Successor Agent and its successors and assigns, all of its rights, title and interest in and to the Agreements.

This Assignment may be executed in any number of counterparts, each of which when so executed shall be deemed an original and all of which taken together shall constitute one and the same instrument.

- Remainder of Page Intentionally Left Blank; Signature Page Follows -

¹ Healthcare Financial Solutions, LLC is a Delaware limited liability company that does business as HFS Healthcare Financial Solutions, LLC in Alabama, California, Florida, Illinois, Maryland, Missouri, New Jersey, New Mexico and Texas and as HFS Healthcare Financial Solutions in New Hampshire.

IN WITNESS WHEREOF, Retiring Agent and Successor Agent have caused this Assignment to be duly executed as of the date first above written.

RETIRING AGENT:

**GENERAL ELECTRIC CAPITAL
CORPORATION** as Retiring Agent

By: 

Name: H. Darren Alcus

Title: Duly Authorized Signatory

SUCCESSOR AGENT:

**HEALTHCARE FINANCIAL
SOLUTIONS, LLC**, as Successor Agent

By: 

Name: H. Darren Alcus

Title: Duly Authorized Signatory

EXHIBIT A

Trademark Security Agreement dated as of February 22, 2013 and filed with the United States Patent and Trademark Office on February 27, 2013 at Reel 4971, Frame 0368 and Corrective Assignment thereto filed with the United States Patent and Trademark Office on March 6, 2013 at Reel 4975, Frame 0830

Patent Security Agreement dated as of February 22, 2013 filed with the United States Patent and Trademark Office on February 28, 2013 at Reel 029893, Frame 0603






EXHIBIT B

Trademark Registrations


1. REGISTERED TRADEMARKS

<u>Trademark</u>	<u>Registration Number</u>	<u>Registration Date</u>
ARBOR PHARMACEUTICALS, INC.	4146108	May 22, 2012
E.E.S.	1077242	November 15, 1977
E.E.S. 400	1058892	February 15, 1977
EES	1144690	December 30, 1980
ERYDERM	1082192	January 17, 1978
ERYPED	1251456	September 20, 1983
ERY-TAB	1211217	October 5, 1982
ERYTHROCIN (Puerto Rico)	9083	September 23, 1954
ERYTHROCIN (U.S.)	0590748	June 8, 1954
NEOTIC	3544687	December 9, 2008
PCE (Puerto Rico)	30441	January 15, 1992
PCE (U.S.)	1437037	April 21, 1987
PEDIADERM	3881019	November 23, 2010
XYLAREX	3632499	June 2, 2009
ZINOTIC	3350351	December 4, 2007

<u>Trademark</u>	<u>Registration Number</u>	<u>Registration Date</u>
BIDIL (Canada)	TMA621207	September 30, 2004
BIDIL (Europe)	2324184	June 27, 2003
BIDIL (U.S.)	1896747	May 30, 1995
HEART HEALTH HERITAGE (Europe)	4252029	February 15, 2006
HEART HEALTH HERITAGE (U.S.)	3604276	April 7, 2009
HEART HERITAGE (Europe)	4588729	August 22, 2006
MAKING TODAY'S BEST MEDICINES BETTER	3092262	May 16, 2006
MORE LIFE TO LIVE	3265101	July 17, 2007
N	3177849	November 28, 2006

 N Logo (Europe)	4151981	April 23, 2007
 N Logo (U.S.)	3904570	January 11, 2011
NITROMED (Europe)	2456580	August 25, 2006
NITROMED (U.S.)	2897976	October 26, 2004
NITROMED (U.S.)	2621465	September 17, 2002
 NITROMED & N Logo (Canada)	TMA810809	November 1, 2011
 NITROMED & N Logo (Europe)	4342432	July 14, 2006
 NITROMED & N Logo (U.S.)	3588941	March 10, 2009
NITROMED CARES	3335303	November 13, 2007

2. TRADEMARK APPLICATIONS

<u>Trademark</u>	<u>Application Number</u>	<u>Application Date</u>
ARBOR PHARMACEUTICALS	85748821	October 9, 2012
EQUADD	85373407	February 7, 2012
EXERSCORE	85560877	March 5, 2012
EXERSCRIPT	85560878	March 5, 2012
NYMALIZE	85404726	August 23, 2011
BALADD	85833131	January 25, 2013
ZENZEDI	85550865	February 23, 2012
BIDIL XR	85154611	October 18, 2010
 N Logo (Canada)	1502939	November 8, 2010
WILSHIRE PHARMACEUTICALS	85749031	October 9, 2012

3. TRADEMARK LICENSES

Trademark License Agreement dated July 1, 2010, by and between Holdings and PharmaScience.

EXHIBIT B

Patent Registrations

1. REGISTERED PATENTS

Grantor has rights in the following registered patents:

<u>Patent Description</u>	<u>Country</u>	<u>Patent Number</u>	<u>Registration Date</u>
Furoxan Compounds Compositions and Methods of Use	US	7,838,023	November 23, 2010
Localized Use of Nitric Oxide Adducts To Prevent Internal Tissue Damage	US	6,087,479	July 11, 2000
Localized Use of Nitric Oxide Adducts To Prevent Internal Tissue Damage	US	6,352,709	March 5, 2002
Localized Use of Nitric Oxide-Adducts To Prevent Internal Tissue Damage	US	6,471,978	October 29, 2002
Localized Use of Nitric Oxide-Adducts To Provent Internal Tissue Damage	US	6,255,277	July 3, 2001
Methods of Treating and Preventing Congestive Heart Failure With Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide	US	6,465,463	October 15, 2002
Methods of Treating and Preventing Congestive Heart Failure With Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide	US	6,784,177	August 31, 2004
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	AU	780261	June 23, 2005
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	CA	2,386,954	December 13, 2011
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	DE	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	EP	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	FR	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	GB	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	IT	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	US	7,235,237	June 26, 2007
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	US	6,635,273	October 21, 2003
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	US	7,708,989	May 4, 2010
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency- (Composition for Treating Vascular Diseases	US	7,537,785	May 26, 2009

Characterized by Nitric Oxide Insufficiency)			
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency-(Transdermal Patch Composition For Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency)	US	7,556,824	July 7, 2009
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	AU	733202	August 23, 2001
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	CA	2,248,800	February 21, 2012
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	US	7,345,037	March 18, 2008
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	US	7,160,920	January 9, 2007
Nitrosated and Nitrosylated Prostaglandins Compositions and Methods of Use	US	7,449,595	November 11, 2008
Nitrosated and Nitrosylated Prostaglandins Compositions and Methods of Use	US	7772278	August 10, 2010
Nitrosated and Nitrosylated Prostaglandins Compositions and Methods of Use	US	7,176,238	February 13, 2007
Nitrosated and nitrosylated taxanes, compositions and methods of use	US	6,656,966	December 2, 2003
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders	US	6,579,863	June 17, 2003
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses	US	5,958,926	September 28, 1999
S-Nitrosothiols As Smooth Muscle Relaxants and Therapeutic Uses Thereof	US	5,380,758	October 10, 1995
Treatment of Male Impotence With S-Nitrosylated Compounds	US	5,648,393	July 15, 1997
Use of Nitric Oxide-Adducts To Prevent Thrombosis On Artificial and Vascular Surfaces	CA	2,170,772	March 29, 2005
Use of Nitric Oxide-Adducts To Prevent Thrombosis On Artificial and Vascular Surfaces	AU	698748	February 18, 1999
Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors	US	8,067,464	November 29, 2011

2. PATENT APPLICATIONS

Grantor has rights in the following patent applications:

<u>Patent Description</u>	<u>Country</u>	<u>Application Number</u>	<u>Filing Date</u>
Compositions for Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency	US	12/564,550	September 22, 2009
Methods for Treating Blood Disorders With Nitric Oxide Donor Compounds	CA	2,561,141	March 31, 2004
Methods for Treating Blood Disorders With Nitric Oxide Donor Compounds	EP	05767498.8	March 31, 2005
Methods for Treating Blood Disorders With Nitric Oxide Donor Compounds	US	10/594990	September 26, 2006
Methods for Treating Respiratory Disorders	AU	2006299383	October 4, 2006
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	AU	2007217980	February 12, 2007
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	CA	2,634,473	February 12, 2007
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	EP	7750648.3	February 12, 2007
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	US	12/096875	August 17, 2008
Methods for Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	CA	2,678,256	May 2, 2001
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	EP	97916818.4	March 19, 1997
Solid Dosage Formulations of Hydrlazine Compounds	CA	2,652,135	May 16, 2007
Solid Dosage Formulations of Hydrlazine Compounds and Nitric Oxide Donor Compounds	US	12/300593	May 6, 2009